Abstract
Twenty-two patients with advanced diffuse large cell lymphoma (LSG classification) were treated with the combination chemotherapy of cyclophosphamide, doxorubicin, methotrexate with leucovorin rescue, bleomycin, vincristine, etoposide, ifosfamide and prednisolone (CAMBO-VIP) from Oct. 1987 to Sept. 1989. Eighteen (90%) of 20 evaluable patients achieved complete remission and 2 patients had partial remission. With a median follow-up of 52 mos, 3 patients relapsed (17%), and 2 patients died. The actuarial overall survival and relapse-free survival at 4 years were estimated to be 90% and 83%, respectively. Myelosuppression was severe, but transient. No serious infection was seen, and no platelet transfusion was required. Oral mucositis and liver damage (Grade 3 in WHO grading) was seen in one patient each, but no treatment-related fatalities were observed. CAMBO-VIP is a well tolerated, effective treatment regimen for advanced diffuse large cell lymphoma.
Publication types
-
Clinical Trial
-
English Abstract
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bleomycin / administration & dosage
-
Bleomycin / adverse effects
-
Bone Marrow / drug effects
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Drug Administration Schedule
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Female
-
Follow-Up Studies
-
Humans
-
Ifosfamide / administration & dosage
-
Ifosfamide / adverse effects
-
Liver / drug effects
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Male
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Middle Aged
-
Prognosis
-
Remission Induction
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Bleomycin
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Ifosfamide
-
Methotrexate